Literature DB >> 24006071

Cell-based methods for the identification of MYC-inhibitory small molecules.

Catherine A Burkhart1, Michelle Haber, Murray D Norris, Andrei V Gudkov, Mikhail A Nikiforov.   

Abstract

Oncoproteins encoded by dominant oncogenes have long been considered as targets for chemotherapeutic intervention. However, oncogenic transcription factors have often been dismissed as "undruggable." Members of Myc family of transcription factors have been identified as promising targets for cancer chemotherapy in multiple publications reporting the requirement of Myc proteins for maintenance of almost every type of tumor. Here, we describe cell-based approaches to identify c-Myc small molecule inhibitors by screening complex libraries of diverse small molecules based on Myc functionality and specificity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24006071      PMCID: PMC4577296          DOI: 10.1007/978-1-62703-429-6_18

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

1.  N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation.

Authors:  B A Malynn; I M de Alboran; R C O'Hagan; R Bronson; L Davidson; R A DePinho; F W Alt
Journal:  Genes Dev       Date:  2000-06-01       Impact factor: 11.361

2.  Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination.

Authors:  M K Mateyak; A J Obaya; S Adachi; J M Sedivy
Journal:  Cell Growth Differ       Date:  1997-10

3.  c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle.

Authors:  H Wang; S Mannava; V Grachtchouk; D Zhuang; M S Soengas; A V Gudkov; E V Prochownik; M A Nikiforov
Journal:  Oncogene       Date:  2007-10-01       Impact factor: 9.867

Review 4.  The Myc oncoprotein as a therapeutic target for human cancer.

Authors:  Marina Vita; Marie Henriksson
Journal:  Semin Cancer Biol       Date:  2006-08-03       Impact factor: 15.707

Review 5.  Conditional transgenic models define how MYC initiates and maintains tumorigenesis.

Authors:  Constadina Arvanitis; Dean W Felsher
Journal:  Semin Cancer Biol       Date:  2006-07-21       Impact factor: 15.707

Review 6.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

Review 7.  The c-Myc target gene network.

Authors:  Chi V Dang; Kathryn A O'Donnell; Karen I Zeller; Tam Nguyen; Rebecca C Osthus; Feng Li
Journal:  Semin Cancer Biol       Date:  2006-07-25       Impact factor: 15.707

8.  MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells.

Authors:  J H Schulte; S Lindner; A Bohrer; J Maurer; K De Preter; S Lefever; L Heukamp; S Schulte; J Molenaar; R Versteeg; T Thor; A Künkele; J Vandesompele; F Speleman; H Schorle; A Eggert; A Schramm
Journal:  Oncogene       Date:  2012-04-09       Impact factor: 9.867

Review 9.  The MYC oncogene as a cancer drug target.

Authors:  Heiko Hermeking
Journal:  Curr Cancer Drug Targets       Date:  2003-06       Impact factor: 3.428

10.  Modelling Myc inhibition as a cancer therapy.

Authors:  Laura Soucek; Jonathan Whitfield; Carla P Martins; Andrew J Finch; Daniel J Murphy; Nicole M Sodir; Anthony N Karnezis; Lamorna Brown Swigart; Sergio Nasi; Gerard I Evan
Journal:  Nature       Date:  2008-08-17       Impact factor: 49.962

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.